SK bioscience has applied for emergency use approval for Novavax’s updated Covid-19 vaccine.
The flu season is back in full swing, and so is SK bioscience’s production of Korea’s first and only cell-based influenza vaccine.
SK bioscience swung to a loss in the second quarter of 2023 due to weak vaccine sales and contract manufacturing organization (CMO) orders.
SK bioscience has signed a memorandum of understanding (MOU) with Thailand’s Government Pharmaceutical Organization (GPO) to establish vaccine infrastructure in the Southeast Asian country.
SK bioscience and Sanofi completed the Phase II clinical trial for a pneumococcal vaccine that the companies are jointly developing, the Korean pharmaceutical company said Friday.
SK bioscience has signed an agreement with the Australia-based Peter Doherty Institute for Infection and Immunity to cooperate on influenza vaccine development.
SK bioscience’s SKYCovione, Korea’s first domestically developed Covid-19 vaccine, was listed for emergency use by the World Health Organization (WHO).
SKYCovion, Korea’s first homegrown Covid-19 vaccine, was approved for sale by Britain's Medicines and Healthcare Products Regulatory Agency (MHRA), developer SK bioscience said Tuesday.
The RVMC is an international framework kicked off during the World Economic Forum in Davos in May last year, with the goal of resolving inequality in the vaccine supply.
SK bioscience inked a manufacturing deal with MSD for an Ebola vaccine candidate.
Korea JoongAng Daily Sitemap